Atlas Trials

Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer

Clinical trial NCT03850769 · UNKNOWN

Trial details

NCT number
NCT03850769
Sponsor
Peking Union Medical College Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Borderline Resectable Pancreatic Cancer
Start date
2019-05-01
Primary completion
2022-03-01
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.